Jumei Announces Share Repurchase PlanMay 28, 2019 at 6:00 AM EDT Company may repurchase up to US$100 million of its shares over the next 12 months. Total hareholder equity as of most recent annual report was $500 000 000 USD , 118.56M shares outstanding. Earnings last year was 24,340 000. you can never be sure about that though because Chinese small caps are notorious for accounting fraud
Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient………… “Announced the publication of a case study involving a cystic fibrosis patient who was successfully treated for a multidrug-resistant Pseudomonas aeruginosa infection with the Company’s natural phage product, AP-PA01. The paper, entitled “Successful adjunctive use of bacteriophage therapy for treatment of multidrug‑resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient,” appears in the peer-reviewed journal Infection”.
10 directors were awarded options with an exercise price of $3.15
Safe-T Group Ltd, $SFET, up 37% on 693,706 shares traded. Excerpt from press release: “Announced the receipt of a purchase order for its Software-Defined Perimeter (SDP) solution from a leading European manufacturer, specializing in the connected devices industry and IOT1 solutions. The customer was looking for a new solution to provide secured remote access to its internal services, as well as to connected lighting cloud platform, for employees, partners, DevOps2 and others. The solution is intended to replace the customer’s existing access solutions and to provide remote access for future services, which the customer plans on launching”…….” The purchase order is for a one-year subscription”. Read more…
Dow erases 100 point gain, currently up 13 points, 11:41:23 AM
Soliton up 125% (12:06pm) on 510(k) clearance for its Rapid Acoustic Pulse (RAP) device for tattoo removal “HOUSTON, May 28, 2019 /PRNewswire/ — Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that it has received clearance from the U.S. Food & Drug Administration (“FDA”) to market its Rapid Acoustic Pulse (“RAP”) device for tattoo removal. The device is indicated as an accessory to the 1064 nm Q-Switched laser for black ink tattoo removal on the arms, legs and torso in Fitzpatrick Skin Type I-III individuals”. Click for full article